These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 36578903)

  • 21. Lambert-Eaton myasthenic syndrome in a patient with small-cell lung cancer: A case report.
    Zhang RR; Han T; Guo F; Liu ZZ; Han YL; Chen WC; Liu YY; Xie XD
    Oncol Lett; 2015 Sep; 10(3):1339-1342. PubMed ID: 26622673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunopathogenesis of myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Lisý L
    Bratisl Lek Listy; 1997 Apr; 98(4):217-20. PubMed ID: 9264830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials.
    Zhang N; Hong D; Ouyang T; Meng W; Huang J; Li M; Hong T
    BMC Neurol; 2021 Sep; 21(1):371. PubMed ID: 34563155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lambert-Eaton myasthenic syndrome - diagnosis, pathogenesis and therapy.
    Hülsbrink R; Hashemolhosseini S
    Clin Neurophysiol; 2014 Dec; 125(12):2328-36. PubMed ID: 25065299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment for Lambert-Eaton myasthenic syndrome.
    Maddison P; Newsom-Davis J
    Cochrane Database Syst Rev; 2003; (2):CD003279. PubMed ID: 12804456
    [TBL] [Abstract][Full Text] [Related]  

  • 26. GRP78 antibodies damage the blood-brain barrier and relate to cerebellar degeneration in Lambert-Eaton myasthenic syndrome.
    Shimizu F; Takeshita Y; Sano Y; Hamamoto Y; Shiraishi H; Sato T; Yoshimura S; Maeda T; Fujikawa S; Nishihara H; Kitanosono H; Tsujino A; Motomura M; Kanda T
    Brain; 2019 Aug; 142(8):2253-2264. PubMed ID: 31236596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lambert-Eaton Myasthenic Syndrome.
    Kesner VG; Oh SJ; Dimachkie MM; Barohn RJ
    Neurol Clin; 2018 May; 36(2):379-394. PubMed ID: 29655456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelling the response to low-frequency repetitive nerve stimulation of myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Miralles F
    Med Biol Eng Comput; 2016 Nov; 54(11):1761-1778. PubMed ID: 27016366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenocarcinoma of Lung Presenting as Lambert-Eaton Myasthenic Syndrome.
    Bukhari S; Soomro R; Fawwad S; Alvarez C; Wallach S
    J Investig Med High Impact Case Rep; 2017; 5(3):2324709617721251. PubMed ID: 28785598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome.
    AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine
    Muscle Nerve; 2001 Sep; 24(9):1239-47. PubMed ID: 11494281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment for Lambert-Eaton myasthenic syndrome.
    Keogh M; Sedehizadeh S; Maddison P
    Cochrane Database Syst Rev; 2011 Feb; 2011(2):CD003279. PubMed ID: 21328260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the decremental pattern in Lambert-Eaton syndrome different from that in myasthenia gravis?
    Sanders DB; Cao L; Massey JM; Juel VC; Hobson-Webb L; Guptill JT
    Clin Neurophysiol; 2014 Jun; 125(6):1274-7. PubMed ID: 24332471
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuromuscular junction disorders beyond myasthenia gravis.
    Oh SJ
    Curr Opin Neurol; 2021 Oct; 34(5):648-657. PubMed ID: 34914667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coexistence of myasthenia gravis and Lambert-Eaton myasthenic syndrome in a small cell lung cancer patient: A case report.
    Jia R; Chen J; Ge R; Zheng Q; Chen F; Zhao Z
    Medicine (Baltimore); 2018 Jun; 97(23):e10976. PubMed ID: 29879051
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 3,4-Diaminopyridine for the treatment of myasthenia gravis with electrophysiological patterns of Lambert-Eaton myasthenic syndrome.
    Lee MK; Sunwoo IN; Kim SM
    J Clin Neurosci; 2018 Apr; 50():194-198. PubMed ID: 29402568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis.
    Guidon AC
    Continuum (Minneap Minn); 2019 Dec; 25(6):1785-1806. PubMed ID: 31794471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-Month Trial of Whole-Food Plant-Based Diet in a Patient With Coexisting Myasthenia Gravis and Lambert-Eaton Myasthenic Syndrome.
    Kim P; Arnold M; Gunti J
    Am J Lifestyle Med; 2021; 15(3):230-237. PubMed ID: 34025312
    [No Abstract]   [Full Text] [Related]  

  • 40. Exploring the role of immune checkpoint inhibitors in the etiology of myasthenia gravis and Lambert-Eaton myasthenic syndrome: A systematic review.
    Seligman C; Chang YM; Luo J; Garden OA
    Front Neurol; 2022; 13():1004810. PubMed ID: 36698907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.